8-KMaterial AgreementsOther EventsExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (May 13, 2020)

Filed May 13, 2020For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on May 13, 2020, primarily detailing the issuance of $550 million in senior unsecured notes due in 2031. These notes carry a coupon rate of 2.800% and will mature on June 30, 2031. The issuance was completed under an existing indenture, further supplemented by a twenty-first supplemental indenture. This action is significant for investors as it represents a material debt financing event, impacting the company's capital structure and leverage. While the notes are senior unsecured obligations, they are subject to covenants limiting certain liens, sale and leaseback transactions, and consolidation/merger activities, with a change of control clause requiring a 101% repurchase offer. The filing also references a press release from May 11, 2020, announcing the pricing of this offering and the associated underwriting agreement. This debt issuance likely aims to provide the company with capital for general corporate purposes, strategic initiatives, or to refinance existing debt. Investors should monitor how this new debt impacts the company's financial flexibility and its ability to meet future obligations, particularly given the covenants and the change of control provision.

Key Highlights

  • 1Quest Diagnostics issued $550 million in 2.800% senior unsecured notes due 2031.
  • 2The notes mature on June 30, 2031, with interest paid semi-annually.
  • 3The debt issuance was completed under an existing indenture, as supplemented by a twenty-first supplemental indenture.
  • 4Covenants restrict the company from creating certain liens, engaging in specific sale and leaseback transactions, and consolidating or merging assets.
  • 5A change of control triggering event will require the company to offer to repurchase the notes at 101% of the principal amount.
  • 6The company entered into an underwriting agreement with Goldman Sachs, J.P. Morgan, and Mizuho Securities for the offering.
  • 7This filing is related to a public offering priced on May 11, 2020, as announced in a press release.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report the entry into a material definitive agreement, specifically the issuance of $550 million in senior unsecured notes due 2031. It also discloses related agreements and events, such as the underwriting agreement and a press release announcing the pricing of the notes.

The notes have an aggregate principal amount of $550 million, a coupon rate of 2.800%, and mature on June 30, 2031. They are senior unsecured obligations of the company and rank equally with other senior unsecured debt. Interest payments are due on June 30 and December 30 of each year, starting December 30, 2020.

The indenture governing the notes includes covenants that limit the company's ability to create certain liens and enter into specific sale and leaseback transactions. It also restricts the company from consolidating, merging, or transferring substantially all of its assets, and from incurring indebtedness at non-guarantor subsidiaries. Additionally, upon a change of control, the company must offer to repurchase the notes at 101% of their principal amount.

This debt issuance increases Quest Diagnostics' total debt and leverage. While providing capital, it also adds to the company's fixed interest obligations and subjects it to the terms and covenants outlined in the indenture. Investors should assess how this new debt affects the company's debt-to-equity ratio, interest coverage, and overall financial flexibility.